Treatment for Patients With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD)
Treatment for Patients With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD)
The purpose of this research is to study the efficacy and safety of AMG 073 in patients with
 kidney failure who are being treated with hemodialysis or peritoneal dialysis and who also
 have secondary hyperparathyroidism (HPT).
Inclusion Criteria: - Completed one of the qualifying studies (i.e., patient previously
 took part in an Amgen study investigating the drug AMG 073 and its effects on secondary
 hyperparathyroidism [HPT]; in particular parathyroid hormone [PTH], calcium and phosphorus
 levels in blood associated with kidney failure) - Must agree to use, in the opinion of the
 principal investigator, highly effective contraceptive measures throughout the study
 Exclusion Criteria: - Pregnant or nursing females - Experienced a myocardial infarction
 within 3 months before day 1 - Have an unstable medical condition, defined as having been
 hospitalized, other than for dialysis vascular access revision, within 30 days before day
 1, or otherwise unstable in the judgment of the investigator